TB Alliance Names Sandeep Juneja as Senior Vice President for Market Access

Juneja Brings Industry Expertise to Initiatives that Accelerate Access to New TB Drug Regimens

June 4, 2018

NEW YORK (June 4, 2018) – TB Alliance today announced the appointment of Sandeep Juneja to Senior Vice President for Market Access. Mr. Juneja joins TB Alliance from Medicines Patent Pool in Geneva, where he forged alliances with companies, research institutes, and other public health stakeholders to increase access to tuberculosis (TB), HIV, and Hepatitis C medicines.

In his new role, Mr. Juneja will lead TB Alliance’s work in the design and implementation of market interventions and access strategies for rapid adoption and uptake of new TB regimens around the world, focusing on countries most affected by tuberculosis.

“It takes far too long for drugs to move from research and development to the market,” said Mr. Juneja. “TB is the world's deadliest infectious disease; patients don’t have time to wait out these delays. I am passionate about shortening the gap between these two phases so that people in high-burden countries who are in desperate need of new TB drugs can access the treatments at the earliest.”

Mr. Juneja has 17 years of experience in the private sector and was responsible for building an HIV and malaria franchise in developing countries that resulted in access to HIV medicines in more than 60 countries and development of an investigational medicine for malaria. He has also has served on several committees and panels addressing access to medicines, such as the Advisory Board of the Medicines4All Institute, Steering Committee on Universal Access, Global Fund Procurement Advisory Panel, and Global Fund Market Dynamics Advisory Group.

“Today, TB Alliance’s portfolio includes improved treatments for children, novel TB drugs and regimens in clinical development, and a robust discovery pipeline—more than 30 active projects in all,” said Dr. Mel Spigelman, President and CEO of the TB Alliance. “We are excited to have Mr. Juneja on board with the immediate goal of bringing the late stage regimens to the market so they can reach the people who need them most as quickly as possible.”

Mr. Juneja is an engineer by training and holds a bachelor’s degree in technology from the Indian Institute of Technology and an MBA in International Business from the Indian Institute of Foreign Trade.


About TB Alliance

TB Alliance is a not-for-profit organization dedicated to finding faster-acting and affordable drug regimens to fight tuberculosis (TB). Through innovative science and with partners around the globe, we aim to ensure equitable access to faster, better TB cures that will advance global health and prosperity. TB Alliance operates with support from Australia’s Department of Foreign Affairs and Trade, Bill & Melinda Gates Foundation, Germany’s Federal Ministry of Education and Research through KfW, Global Health Innovative Technology Fund, Irish Aid, Indonesia Health Fund, National Institute of Allergy and Infectious Disease, Netherlands Ministry of Foreign Affairs, United Kingdom Department for International Development, United States Agency for International Development, and the United States Food and Drug Administration.